Advanced search
Publication Cover
Orbit
The International Journal on Orbital Disorders, Oculoplastic and Lacrimal Surgery
Volume 43, 2024 - Issue 2
Submit an article Journal homepage
202
Views
0
CrossRef citations to date
0
Altmetric
Research article

A comparison of proptosis reduction with teprotumumab versus surgical decompression based on fat-to-muscle ratio in thyroid eye disease

Michelle A. J. Tinga Division of Oculofacial Plastic and Reconstructive Surgery, University of California San Diego Viterbi Family Department of Ophthalmology, Shiley Eye Institute, San Diego, California, USACorrespondence[email protected]
View further author information
,
Nicole J. Topilowa Division of Oculofacial Plastic and Reconstructive Surgery, University of California San Diego Viterbi Family Department of Ophthalmology, Shiley Eye Institute, San Diego, California, USAView further author information
,
Lilangi S. Ediriwickremab Division of Oculofacial Plastic and Reconstructive Surgery, Department of Ophthalmology, Gavin Herbert Eye Institute, University of California Irvine, Irvine, California, USA;c Department of Ophthalmology, Gavin Herbert Eye Institute, University of California Irvine, Irvine, California, USAView further author information
,
Jin Sook Yoond Department of Ophthalmology, Severance Hospital, Institute of Vision Research, Yonsei University College of Medicine, Seoul, KoreaView further author information
,
Catherine Y. Liua Division of Oculofacial Plastic and Reconstructive Surgery, University of California San Diego Viterbi Family Department of Ophthalmology, Shiley Eye Institute, San Diego, California, USAView further author information
,
Bobby S. Korna Division of Oculofacial Plastic and Reconstructive Surgery, University of California San Diego Viterbi Family Department of Ophthalmology, Shiley Eye Institute, San Diego, California, USA;e Division of Plastic and Reconstructive Surgery, UC San Diego Department of Surgery, San Diego, California, USAView further author information
&
Don O. Kikkawaa Division of Oculofacial Plastic and Reconstructive Surgery, University of California San Diego Viterbi Family Department of Ophthalmology, Shiley Eye Institute, San Diego, California, USA;e Division of Plastic and Reconstructive Surgery, UC San Diego Department of Surgery, San Diego, California, USAView further author information
 show all
Pages 222-230 | Received 12 Jul 2023, Accepted 07 Nov 2023, Published online: 17 Nov 2023

References

  • Kozaki A, Inoue R, Komoto N, Maeda T, Inoue Y, Inoue T, et al. Proptosis in dysthyroid ophthalmopathy: a case series of 10,931 Japanese cases. Optom Vis Sci Off Publ Am Acad Optom. 2010;87(3):200–204. doi:10.1097/OPX.0b013e3181ce5702.
  • Rootman Daniel B. Orbital decompression for thyroid eye disease. Surv Ophthalmol. 2018;63(1):86–104. doi:10.1016/j.survophthal.2017.03.007.
  • Ediriwickrema LS, Korn BS, Kikkawa DO. Orbital decompression for thyroid-related orbitopathy during the quiescent phase. Ophthal Plast Reconstr Surg. 2018;34(4S Suppl 1):S90–S7. doi:10.1097/IOP.0000000000001119.
  • Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341–352. doi:10.1056/NEJMoa1910434.
  • Uddin JM, Rubinstein T, Hamed-Azzam S. Phenotypes of thyroid eye disease. Ophthal Plast Reconstr Surg. 2018;34(4S Suppl 1):S28–S33. doi:10.1097/IOP.0000000000001147.
  • Nunery WR, Tao J. Thyroid orbitopathy. Ophthalmology. 2007;114(3):621–2; author reply 622. doi:10.1016/j.ophtha.2006.08.026.
  • Nunery WR, Martin RT, Heinz GW, Gavin TJ. The association of cigarette smoking with clinical subtypes of ophthalmic Graves’ disease. Ophthal Plast Reconstr Surg. 1993;9(2):77–82. doi:10.1097/00002341-199306000-00001.
  • Nunery WR. Ophthalmic Graves’ disease: a dual theory of pathogenesis. Ophthalmol Clin North Am. 1991;4:73–87.
  • Ting MA, Ozzello DJ, Topilow NJ, Yoon JS, Liu CY, Korn BS, et al. Differential effects of teprotumumab treatment based on fat-to-muscle ratio in patients with thyroid eye disease. Orbit Amst Neth. 2023;2022:418–425. doi:10.1080/01676830.2022.2122515.
  • Sears CM, Azad AD, Amarikwa L, PhamJ BH, MenN C, Kaplan D, et al. Hearing dysfunction after treatment with teprotumumab for thyroid eye disease. Am J Ophthalmol. 2022;240:1–13. doi:10.1016/j.ajo.2022.02.015.
  • Hoang TD, Nguyen NT, Chou E, Shakir MK. Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease. BMJ Case Rep. 2021;14(5):e242153. doi:10.1136/bcr-2021-242153.
  • Highland J, Gordon S, Reddy D, Patel N. Ototoxicity and Teprotumumab. Ann Otol Rhinol Laryngol. 2022;131(8):910–913. doi:10.1177/00034894211042740.
  • Ozzello Daniel J, Kikkawa Don O, Korn Bobby S. Early experience with teprotumumab for chronic thyroid eye disease. Am J Ophthalmol Case Rep. 2020;19:100744. doi:10.1016/j.ajoc.2020.100744.
  • Dik WA, Virakul S, van Steensel L. Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves’ ophthalmopathy. Exp Eye Res. 2016;142:83–91. doi:10.1016/j.exer.2015.02.007.
  • Girnita L, Smith TJ, Janssen JAMJL. It takes two to tango: IGF-I and TSH receptors in thyroid eye disease. J Clin Endocrinol Metab. 2022;107(Suppl_1):S1–12. doi:10.1210/clinem/dgac045.
  • Pritchard J, Horst N, Cruikshank W, Smith TJ. Igs from patients with Graves’ disease induce the expression of T cell chemoattractants in their fibroblasts. J Immunol Baltim Md 1950. 2002;168(2):942–950. doi:10.4049/jimmunol.168.2.942.
  • Pritchard J, Han R, Horst N, Cruikshank WW, Smith TJ. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves’ disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol Baltim Md 1950. 2003;170(12):6348–6354. doi:10.4049/jimmunol.170.12.6348.
  • Tsui S, Naik V, Hoa N, Hwang CJ, Afifiyan NF, Sinha HA, et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves’ disease. J Immunol Baltim Md 1950. 2008;181(6):4397–4405. doi:10.4049/jimmunol.181.6.4397.
  • Zhao P, Deng Y, Gu P, Wang Y, Zhou H Hu Y, et al. Insulin-like growth factor 1 promotes the proliferation and adipogenesis of orbital adipose-derived stromal cells in thyroid-associated ophthalmopathy. Exp Eye Res. 2013;107:65–73. doi:10.1016/j.exer.2012.11.014.
  • Yoshida T, Delafontaine P. Mechanisms of IGF-1-Mediated regulation of skeletal muscle hypertrophy and atrophy. Cells. 2020;9(9):1970. doi:10.3390/cells9091970.
  • Ugradar S. LBSAT238 teprotumumab reduces orbital fat and muscle volume in patients with thyroid eye disease. J Endocr Soc. 2022;6(Supplement_1):A744. doi:10.1210/jendso/bvac150.1535.
  • Douglas RS, Kahaly GJ, Ugradar S, Elflein H, Ponto KA, Fowler BT, et al. Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study. Ophthalmology. 2022;129(4):438–449. doi:10.1016/j.ophtha.2021.10.017.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.